IP Verse

Hyaluronic Acid-Based Gels Including Anesthetic Agents - EP2674147

The patent EP2674147 was granted to Allergan Industrie on Jan 1, 2020. The application was originally filed on Mar 2, 2009 under application number EP13004017A. The patent is currently recorded with a legal status of "Revoked".

EP2674147

ALLERGAN INDUSTRIE
Application Number
EP13004017A
Filing Date
Mar 2, 2009
Status
Revoked
Jul 15, 2022
Grant Date
Jan 1, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GALDERMA HOLDINGSep 30, 2020AERAADMISSIBLE
MERZ PHARMASep 30, 2020WALLINGER RICKER SCHLOTTER TOSTMANNADMISSIBLE

Patent Citations (28) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2006194758
DESCRIPTIONUS6921819
EXAMINATIONWO2008068297
OPPOSITIONUS2005136122
OPPOSITIONUS2006194758
OPPOSITIONUS6921819
OPPOSITIONWO2004032943
OPPOSITIONWO2005066215
OPPOSITIONWO2005067944
OPPOSITIONWO2005112888
OPPOSITIONWO2008068297
OPPOSITIONWO9633751
OTHEREP2326302
OTHERUS2006194758
OTHERUS2006246137
OTHERUS6685963
OTHERWO2005112888
OTHERWO2008068297
OTHERWO2010015900
OTHERWO2010015901
OTHERWO2010052430
SEARCHUS2005136122
SEARCHUS2005142152
SEARCHUS2006194758
SEARCHUS2006246137
SEARCHUS6685963
SEARCHWO2005112888
SEARCHWO2007128923

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- "JUVÉDERM ULTRA", INTERNET CITATION, (20080201), pages 1 - 3, URL: HTTP://WWW.CONSULTINGROOM.COM/TREATMENTS/JUVEDERM-ULTRA, (20150801), XP003036055-
EXAMINATION- LEVY P ET AL, "A SPLIT-FACE COMPARISON OT TWO HYALURONIC ACID FACIAL FILLERS IN THE TREATMENT OF NASO-LABIAL FOLDS", IMCAS ( INTERNATIONAL MASTER COURSE ON AGING SKIN ) 2008; 9-12 JANUARY, 2008; PARIS-FRANCE,, (20080109), page 1, XP003036054-
EXAMINATION- ENDRE A BALAZS ET AL, THERAPEUTIC USE OF HYALURONAN-BASED PRODUCTS, CARBOHYDRATE CHEMISTRY, BIOLOGY AND MEDICAL APPLICATIONS; [31969],, PAGE(S) I-IV, (20080101), ISBN 978-0-08-054816-6, XP003036056
OPPOSITION- "5359: Lidocaine", Susan Budavari et al, THE MERCK INDEX AN ENCYCLOPEDIA OF CHEMICALS, DRUGS, AND BIOLOGICALS. 11th Ed., Merk & CO, (1989), page 5360, XP055740793-
OPPOSITION- Allergan, "Package insert of Juvéderm® ULTRA 3", Allergan, (2007), XP055429983-
OPPOSITION- Anika Therapeutics, "Cross-linked hyaluronic acid and lidocaine injectable gel for intradermal use", Elevess, (20060000), pages 1 - 14, XP055740014-
OPPOSITION- Anonymous, "Dermal filler product comparison", The European Aesthetic Guide, (20080301), pages 120 - 122, XP055306736-
OPPOSITION- Anonymous, "Dermal filler product comparison", The European Anesthetic Guide, (20080000), pages 120 - 122, XP055306736-
OPPOSITION- Anonymous, "Elevess™", Anika Therapeutics - Product Information, (200807), XP055740178-
OPPOSITION- Anonymous, "Juvéderm® ULTRA", CONSULTING ROOM, (20080201), pages 1 - 3, URL: www.consultingroom.com, XP003036055-
OPPOSITION- Budavari S,, M. J. Oneil, Smith A, P. E. Heckelman, "Lidoflazine", Budavari S,, M. J. Oneil, Smith A, P. E. Heckelman, Budavari S,, M. J. Oneil, Smith A, P. E. Heckelman, The Merck Index:  An Encyclopedia of Chemicals, Drugs, and Biologicals, 11th ed., (19890000), page 5360, XP055740038-
OPPOSITION- Falbe Jurgen, M. Regity, "Lidocain", RÖMPP Lexikon Chemie, 10. Auflage, (19970000), page 2405, XP055740025-
OPPOSITION- Kevin C Smith, "Practical use of Juvéderm: early experience", Plast Reconstr Surg, (20070000), vol. 120, no. 6 Suppl, pages 67S - 73S, XP055739967-
OPPOSITION- LEVY et al., "Comparison of Injection Comfort and Ease with Juvéderm Ultra 3 and Surgiderm 30 XP", Poster presented at International Master Course on Aging Skin (IMCAS), Paris, France, (20080109), XP055429940-
OPPOSITION- LEVY P. et al., "A Split-Face Comparison of Two Hyaluronic Acid Facial Fillers in the Treatment of Naso-Labial Folds", Abstract of poster presented at the Anti-Aging Medicine World Congress (AMWC), Paris, France, (20080109), XP003036054-
OPPOSITION- LEVY P; RASPALDO H; DE BOULLE K, "A SPLIT-FACE COMPARISON OT TWO HYALURONIC ACID FACIAL FILLERS IN THE TREATMENT OF NASO-LABIAL FOLDS", AWMC, (20080000), page 138, XP003036054-
OPPOSITION- Nadine Hagedorn, "Test Report (Comparative Tests)", Merz Pharmaceuticals, (20171004), pages 1 - 7-
OPPOSITION- Pharm-Illergan, "Juvederm® ULTRA: eine neue Filler-Dimension nun in Europaverfugbar / Neuer und sanfter Filler fur Gesichtsfalten verspricht eine nahezu schmerzfreie Behandlung mit lang anhaltenden Ergebnissen", Press release of Allergan, (20080111), XP055740785-
OPPOSITION- WAHL, GREGOR, "The Juvéderm ULTRA European Expert Evaluation, Abstract of poster presented", Anti-Aging Medicine World Congress (AMWC), Paris, France, (20080410), XP055429967-
OPPOSITION- Ahmet Tezel; Glenn H Fredrickson, "The science of hyaluronic acid dermal fillers", J. Cosmetic and Laser Therapy, (20080000), vol. 10, pages 35 - 42, XP055248256
OPPOSITION- ALLEMANN L. et al., "Hyaluronic acid gel (Juvéderm™) preparations in the treatment of facial wrinkles and folds", Clinical Interventions in Aging, (20081200), vol. 3, no. 4, pages 629 - 634, XP002623290
OTHER- "Juvéderm ultra 3", Package insert, (20120925), XP055469433-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents